Addex Appoints Laurent Galibert Head of Inflammation Business Unit
30-Jul-2008
Addex Pharmaceuticals announced the appointment of Laurent Galibert to its executive management team, as head of the Addex inflammation Business Unit.
Immediately prior to joining Addex Dr. Galibert was senior staff scientist at Merck Serono. From 1996-2005 he held successive research positions at Immunex Corp. (acquired by Amgen Inc.) and Amgen, where he cloned the receptor activator of nuclear factor kappa B ligand (RANKL) and co-authored the initial patent leading to the development of Amgen's denosumab, a monoclonal antibody against RANKL, which is in Phase III development for postmenopausal osteoporosis and in clinical development for other indications. From 1991-1995 Dr. Galibert was a PhD fellow at Schering-Plough.
Other news from the department people
